We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: FDA Unlikely to Approve More Omnitropes Without Industry Pressure
Expert: FDA Unlikely to Approve More Omnitropes Without Industry Pressure
June 13, 2006
Drug companies that want to market follow-on biologically derived products should temper their enthusiasm over the FDA's recent approval of Omnitrope, as future approvals will most likely require court battles with the agency or congressional intervention, according to one patent attorney and the FDA itself.